Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

7.1%

1 terminated/withdrawn out of 14 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

71%

10 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

9(64.3%)

N/A

2(14.3%)

Phase 1

2(14.3%)

Phase 4

1(7.1%)

14Total

Phase 3(9)

N/A(2)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT05204589Phase 3Completed

Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Role: collaborator

NCT03992274Not ApplicableTerminated

Biomedical HIV/AIDS Prevention Program Yunnan

Role: collaborator

NCT04470609Phase 1Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

Role: collaborator

NCT04412538Phase 1Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Role: collaborator

NCT04224519Phase 4Completed

Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain

Role: collaborator

NCT06041061Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Role: collaborator

NCT05662020Phase 3Active Not Recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Role: collaborator

NCT05163652Phase 3Unknown

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above

Role: collaborator

NCT05164731Phase 3Unknown

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above

Role: collaborator

NCT04689191Phase 3Unknown

A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine

Role: collaborator

NCT04689165Phase 3Unknown

A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine

Role: collaborator

NCT03852849Not ApplicableUnknown

Rapid Build of HIV Related Protective Barriers

Role: collaborator

NCT01108614Phase 3Unknown

Injecting Drug Use Community Intervention Trial

Role: collaborator

NCT01068015Phase 3Unknown

(Men Who Have Sex With Men) MSM Community Intervention Trial

Role: collaborator

All 14 trials loaded